Report : North America Travel Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Hepatitis A, Hepatitis B, Meningococcal Vaccines, and Others) and Application (Domestic Travel and Outbound Travel)
Outbound Travel Segment to Dominate North America Travel Vaccines Market during 2020–2028
According to a new market research study on “North America Travel Vaccines Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product and Application” is expected to reach US$ 2,503.59 million by 2028 from 1,276.32 US$ million in 2021. The market is estimated to grow at a CAGR of 10.1% from 2021 to 2028. The report provides trends prevailing in the North America travel vaccines market along with the drivers and restraints pertaining to the market growth. Significant surge in travel and tourism is the major factor driving the growth of the North America travel vaccines market. However, issues associated with high cost of travel vaccines hinders the growth of North America travel vaccines market.
North America travel vaccines market is segmented into product, application, and country. The North America travel vaccines market, by product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. In 2021, the others segment held the largest share of the market. By application, the North America travel vaccines market is segmented into domestic and outbound travel. In 2021, the outbound travel segment held the largest share of the market. Based on country, the North America travel vaccines market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2021.
Abbott; Dynavax Technologies; Emergent BioSolutions Inc.; GlaxoSmithKline plc; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Sanofi; and Valneva SE. are among the leading companies in the North America travel vaccines market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, GlaxoSmithKline plc and Vir Biotechnology, Inc. had signed a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses.
Contact Person: Sameer Joshi
Email Id: email@example.com